Bruce Booth

Bruce Booth is a partner at Atlas Venture and an early-stage venture capitalist focused on biotech investing.14 He is the Chairman of the Board of Directors at Matchpoint Therapeutics, a role he has held since April 2021.43

Booth has extensive experience in the biotech industry, serving as chairman or board member for numerous companies. He is currently chairman of Arkuda Therapeutics, Hotspot Therapeutics, Kymera Therapeutics (NASDAQ: KYMR), Nimbus Therapeutics, and Vigil Neuroscience (NASDAQ: VIGL).5 He also serves on the boards of Sionna Therapeutics and other seed-stage companies.5

Booth holds a D.Phil. (Ph.D.) in molecular immunology from Oxford University, where he studied as a British Marshall Scholar, and a BS in biochemistry, summa cum laude, from Penn State University.14 Prior to joining Atlas Venture in 2005, he worked as a consultant at McKinsey & Company and as an investor for Caxton Health Holdings.14

In addition to his professional roles, Booth is active in the biotech community. He blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes.2 He also serves as an advisor to various organizations, including Takeda, UCB, and the Gates Foundation.15